GlassScriptPhysician profile
Chukwuemeka Oragwu
NPI 1932385911
$2,954.87
in general payments reported to CMS, 2019-2025
20 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.22 · 2021: $90.10 · 2022: $181 · 2023: $199 · 2024: $2,320 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $2,083 · Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $2,083.37 |
| Food and Beverage | $585.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Photonicare INC | $2,083.37 | 2024 | Otosight Middle Ear Scope |
| Glaxosmithkline, LLC. | $92.29 | 2022-2025 | Shingrix, Arexvy |
| Pfizer INC. | $88.18 | 2022-2024 | |
| Exeltis, USA INC. | $84.93 | 2022-2025 | Slynd |
| Lilly USA, LLC | $82.89 | 2021-2024 | Jardiance |
| Dexcom, INC. | $64.21 | 2021-2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $58.04 | 2022 | |
| Exact Sciences Corporation | $54.99 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $49.90 | 2021-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $46.08 | 2024-2025 | Rybelsus |
| Novartis Pharmaceuticals Corporation | $41.30 | 2021-2022 | |
| Evoke Pharma, INC. | $39.00 | 2023-2024 | Gimoti |
| Hologic Sales and Service, LLC | $28.43 | 2024 | Aptima |
| Genentech USA, INC. | $27.32 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.90 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $19.91 | 2023 | Farxiga |
| Amgen INC. | $18.49 | 2024 | Krystexxa |
| Abiomed | $17.57 | 2025 | |
| Paratek Pharmaceuticals, INC. | $16.44 | 2024 | Nuzyra |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.63 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chukwuemeka Oragwu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.